Olema Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Olema Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 82% of its market value (net cash). Higher than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-130.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 87% of Healthcare companies in United States.
Cash Cushion Ratio
+82%Cash, after subtracting all debt, equals 82% of its market value (net cash).
Higher than 85% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Olema Pharmaceuticals, Inc. made a loss over the last year. Olema Pharmaceuticals, Inc. owes $0.12 for every $1 it owns. Olema Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOlema Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.30The share price is 1.30 times Olema Pharmaceuticals, Inc.'s book value per share, lower than 72% of Healthcare companies in United States.
Market cap
$561 MThe total market value of all of Olema Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$431 MWhat Olema Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.92Net worth divided by the number of shares. The share price of $6.41 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-52.7%Olema Pharmaceuticals, Inc. lost 52.7% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
Owes vs Owns
0.12×Olema Pharmaceuticals, Inc. owes $0.12 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Dividend yield
NoneOlema Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossOlema Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashOlema Pharmaceuticals, Inc. held $501 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Olema Pharmaceuticals, Inc.: $561 M ÷ $431 M (30 Jun 2026) = 1.3.
What is Olema Pharmaceuticals, Inc.'s return on equity?
Olema Pharmaceuticals, Inc. lost 52.7% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
How much does Olema Pharmaceuticals, Inc. owe compared with what it owns?
Olema Pharmaceuticals, Inc. owes $0.12 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Does Olema Pharmaceuticals, Inc. pay a dividend?
No. Olema Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.